Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: November 12, 2020

About 90% of Clinical Data Used for FDA Approval is From Non-US Sites

April 25, 2025November 12, 2020 by iwewlkws

While it is well known that FDA accepts clinical trial data from anywhere so long as it meets certain quality standards, the full extent of the impact of this policy comes out in a report released by FDA this week. According to the report, almost 90% of the clinical data that was used for approval … Read more

Categories Blog

Five Ways Pfizer’s Covid Vaccine Changes the Life For All Other Covid Vaccines

April 25, 2025November 12, 2020 by iwewlkws

This week, Pfizer’s announcement that its Covid vaccine is 90% effective upended the path to market for all other vaccines in development. There are 10 other vaccines currently in Phase 3 clinical trials; additionally there are 14 in Phase 2, and 38 in Phase 1 clinical trials worldwide, all of which have a new world … Read more

Categories Blog

Recent Posts

  • FDA’s White Paper Emphasizes that Quality Pays
  • How Registration Can Rescue Observational Studies from Bias and Hype
  • How the FDA and Doctors Can Reassure Patients About AI
  • EHRs Weren’t Built for Science — Here’s How to Fix That  
  • The Case Against 2:1 Randomization: Why Equal Allocation Still Wins  

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.